Rani Therapeutics Secures Up To $1.085B Chugai Partnership, Raises $60.3M Capital
Summary
Rani Therapeutics announced its fourth quarter and full year 2025 financial results, alongside a significant corporate update. The company secured a collaboration and license agreement with Chugai Pharmaceutical Co. potentially worth up to $1.085 billion for multiple therapeutics, a highly material deal for a company of Rani's size. Concurrently, Rani completed an oversubscribed private placement, raising $60.3 million and strengthening its balance sheet. Additionally, Rani initiated a Phase 1 clinical study for RT-114, a bispecific GLP-1/GLP-2 dual agonist for obesity, and reported positive preclinical data for both RT-114 and oral semaglutide delivered via its RaniPill® capsule. These developments represent substantial validation of Rani's platform, provide significant capital, and advance its key pipeline assets into clinical stages, marking a critical inflection point for the company.
At the time of this announcement, RANI was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $131.2M. The 52-week trading range was $0.39 to $3.87. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.